Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178607
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSato, Mai-
dc.contributor.authorRodriguez Barrueco, Ruth-
dc.contributor.authorYu, Jiyang-
dc.contributor.authorDo, Catherine-
dc.contributor.authorSilva, Jose M.-
dc.contributor.authorGautier, Jean-
dc.date.accessioned2021-06-21T17:01:18Z-
dc.date.available2021-06-21T17:01:18Z-
dc.date.issued2014-12-26-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/2445/178607-
dc.description.abstractMYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumorigenic phenotype. While direct targeting of MYC is difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively inhibit their growth. Using a genome-wide shRNA screen, we identified 78 candidate genes, which are required for survival of human mammary epithelial cells with elevated MYC levels. Among the candidates, we validated and characterized FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation. Down-regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-bound MYC, while protein levels of other FBXW7 targets appear unaffected. Over a four-week time course, continuous FBXW7 down-regulation and MYC activation together cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle. Under these conditions, we also observe elevated chromatin-bound levels of CDC45, suggesting increased DNA replication stress. Consistent with these results, FBXW7 down-regulation alone decreases the survival of T47D breast cancer cells. These results establish that FBXW7 down-regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in breast epithelial cells.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherImpact Journals-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.3203-
dc.relation.ispartofOncotarget, 2014, vol. 6, num. 5, p. 3292-3305-
dc.relation.urihttps://doi.org/10.18632/oncotarget.3203-
dc.rightscc-by (c) Sato, Mai et al., 2014-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationCàncer-
dc.subject.classificationProteïnes-
dc.subject.classificationCèl·lules-
dc.subject.otherCancer-
dc.subject.otherProteins-
dc.subject.otherCells-
dc.titleMYC is a critical target of FBXW7-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec694978-
dc.date.updated2021-06-21T17:01:18Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid25669969-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
694978.pdf1.76 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons